Delivery Order SPE2DB20D3103-SPE2DB25FP8Q4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $21,488.46 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 30, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office and serves as a major...
- The Defense Logistics Agency awarded a delivery order valued at $5,007.60 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Trelegy Ellipta is a combination maintenance inhaler used for chronic...
- The Defense Logistics Agency awarded a $28,030.14 delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Trelegy Ellipta is a combination maintenance inhaler used to treat chronic obstructive pulmonary...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $10,524.09 delivery order on July 29, 2025, for Trelegy Ellipta 100-62.5-25 inhalers (60-count). This is a firm fixed-price, competitively awarded contract with performance in Conshohocken, Pennsylvania, and an ultimate completion date of July 30, 2025. The contract carries no set-aside designation. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $11,045.85 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units). The contract, which became effective on July 24, 2025, with an ultimate completion date of July 25, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $25,630.25 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) on August 7, 2025, with completion scheduled for August 8, 2025. This non-competitive, firm fixed-price delivery order was placed against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The product...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,345.60 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count). This contract, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a firm fixed-price delivery order with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $12,545.94 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $40,498.66 firm fixed price delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract, which carries no set-aside designation, was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $13,967.90 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 (60-count inhalers) with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract issued on August 1, 2025, to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Trelegy Ellipta is a maintenance inhaler used for chronic obstructive pulmonary...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP8Q4Delivery Order
The Defense Logistics Agency awarded a $16,902.11 delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) on August 13, 2025, with completion scheduled for August 14, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The pharmaceutical products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. Trelegy Ellipta is a combination inhalation therapy used for chronic obstructive pulmonary disease management, reflecting the company's role in delivering specialty pharmaceutical products to Defense Health Agency customers and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.9k | 8/13/25 |